MAPT and Alzheimer disease: Other tau-targeted therapies in AD include active/passive immunization to target pathological tau species, and a range of small molecules intended to either reduce tau expression, aggregation, and propagation, or promote MT stabilization and tau degradation [49–51]; whether they are efficacious has not been conclusively assessed yet.Therefore, the aim of this study is to identify whether inhibition of tau hyperphosphorylation is a promising strategy for the development of disease-modifying therapies (DMTs) against AD.